BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Turning into a Distributed Writer: My Composing Process - 2EU waters down plans to end new petrol and diesel car sales by 2035
- 3Israel strikes south Lebanon after first direct talks in decades
- 4When does Spotify Wrapped come out? The music streamer says 'soon.'
- 5Step by step instructions to Buy a Jeep Wrangler on a Senior's Spending plan
- The best overlooked performances of 2025
- 6 Top Computer game Control center
- Miley Cyrus flashes a diamond ring on the red carpet, sparking engagement rumors with Maxx Morando: A timeline of their four-year relationship
- The Advancement and Effect of Dental Embed Innovation on Oral Wellbeing
- Instructions to Pick the Right Tires for Your Slam 1500.
- German hauliers warn soaring energy prices may soon impact consumers
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Shrewd Home Gadgets to Save Energy
- Four new luxury hotel openings in Italy you need to know about
